Immunitybio Inc is trading 5.5% down at $6.89 as U.S. equities face a broad selloff and risk assets come under pressure.
- The decline appears macro-driven, with growth and higher-risk names underperforming following stronger-than-expected labor data.
- Investor sentiment has shifted as expectations for near-term Federal Reserve rate cuts are reduced.
- There are no new, material company-specific announcements or catalysts reported for the company so far today.